SCHEMBL6896907

SCHEMBL6896907

CCCC[SiH](Br)CCCC

nearest known ligand 0.40

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.40
LMNA P02545 1/20 0.40
THRB P10828 1/20 0.38
ALDH1A1 P00352 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
SLC22A1 O15245 2/20 0.30
SLC22A2 O15244 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23701097 0.94
SCHEMBL25173762 0.90 TSHR (0.44) TSHRLMNATHRBALDH1A1SLC22A1
SCHEMBL25186671 0.87 TSHR (0.50) TSHRLMNATHRBALDH1A1SLC22A1
SCHEMBL23701305 0.87
SCHEMBL25179829 0.87 TSHR (0.50) TSHRLMNATHRBALDH1A1SLC22A1
SCHEMBL707942 0.79
SCHEMBL6896304 0.77
SCHEMBL23701238 0.76
SCHEMBL21383128 0.74
SCHEMBL8385732 0.69 TSHR (0.46) TSHRLMNATHRBALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11807758-B2 Siloxane polymer and method of producing siloxane polymer JNC CORPORATION (JP) 2023-11-07 US disclosed
WO-2023100914-A1 METHOD FOR MANUFACTURING OLIGOFURAN SKELETON-CONTAINING POLYCARBOSILANE AND OLIGOFURAN SKELETON-CONTAINING POLYCARBOSILANE 国立大学法人群馬大学 2023-06-08 WO disclosed
WO-2023080042-A1 METHOD FOR PRODUCING OLIGOFURAN COMPOUND CONTAINING REACTIVE SILYL GROUP, AND OLIGOFURAN COMPOUND CONTAINING REACTIVE SILYL GROUP 国立大学法人群馬大学 2023-05-11 WO disclosed
US-20210238419-A1 SILOXANE POLYMER AND METHOD OF PRODUCING SILOXANE POLYMER JNC CORPORATION (JP) 2021-08-05 US disclosed
US-8791221-B2 Addition-curable metallosiloxane compound DAICEL CORPORATION (JP) 2014-07-29 US disclosed
EP-2650319-A1 ADDITION-CURABLE METALLOSILOXANE COMPOUND Daicel Corporation (JP) 2013-10-16 EP disclosed
US-20130267653-A1 ADDITION-CURABLE METALLOSILOXANE COMPOUND DAICEL CORPORATION (JP) 2013-10-10 US disclosed
EP-1098926-B1 CROSS-LINKABLE HYPERBRANCHED POLYMERS, METHOD FOR THE PRODUCTION AND USE OF THE SAME BAYER MATERIALSCIENCE AG (DE) 2004-03-03 EP disclosed
EP-1098926-A1 CROSS-LINKABLE HYPERBRANCHED POLYMERS, METHOD FOR THE PRODUCTION AND USE OF THE SAME Bayer Aktiengesellschaft (DE) 2001-05-16 EP disclosed
WO-2000002954-A1 CROSS-LINKABLE HYPERBRANCHED POLYMERS, METHOD FOR THE PRODUCTION AND USE OF THE SAME BAYER AKTIENGESELLSCHAFT (DE) 2000-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130267653-A1 ADDITION-CURABLE METALLOSILOXANE COMPOUND B2M, MSI2, MNS1 TSHR 4702/4885LMNA 383/4885THRB 4049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.